Study of Posterior Reversible Encephalopathy Syndrome in Children With Acute Lymphoblastic Leukemia After Induction Chemotherapy

Abstract

Increasing occurrence of posterior reversible encephalopathy syndrome has been reported in children with acute lymphoblastic leukemia. However, the etiology of posterior reversible encephalopathy syndrome is not clear. To study the possible pathogenetic mechanisms and treatment of this complication, we reported 11 cases of pediatric acute lymphoblastic leukemia who developed posterior reversible encephalopathy syndrome after induction chemotherapy. After appropriate treatment, the clinical symptoms of posterior reversible encephalopathy syndrome in most cases disappeared even though induction chemotherapy continued. During the 1-year follow-up, no recurrence of posterior reversible encephalopathy syndrome was observed. Although the clinical and imaging features of posterior reversible encephalopathy syndrome may be diverse, posterior reversible encephalopathy syndrome should be recognized as a possible important complication of acute lymphoblastic leukemia when neurologic symptoms appear. In line with previous reports, our study also indicated that posterior reversible encephalopathy syndrome was reversible when diagnosed and treated at an early stage. Thus, the occurrence of posterior reversible encephalopathy syndrome should be considered and investigated to optimize the early induction scheme of acute lymphoblastic leukemia treatment.

Posterior Reversible Encephalopathy Syndrome in Children:: A Prospective Follow-up Study

“…7 Chemotherapeutic and immunosuppressive drugs are important risk factors for PRES. 3,[7][8][9][10][11][12][13] In the present study, all the studied children with cancer developed PRES within 24-96 hours of receiving chemotherapeutic drugs and all hematopoietic stem cell transplantation recipients were on cyclosporine therapy when they developed PRES.…”

Microelectrodes Integrated into a Microfluidic Chip for the Detection of CCRF‐CEM Cells Based on the Electrochemical Oxidation of Hydrazine

“…Lymphoblasts excessively multiply in the bone marrow, causing damage and death by inhibiting the reproduction of normal blood cells and infiltrating other organs. ALL is most common in childhood and has a relatively short pathogenesis time . For patients that do not receive any specific treatment, their average survival period is 3 months.…”

“…ALL is most common in childhooda nd has ar elatively short pathogenesist ime. [2] For patients that do not receive any specific treatment, their average survival period is 3months. Therefore, the earlier diagnosis of ALL means ab etter chance of survival for the patients.…”

Posterior Reversible Encephalopathy Syndrome in ALL

“…During 1-year follow-up, all patients continued treatment with ALL chemotherapy, and no PRES symptoms were observed. [ 1 ]…”

“…COMMENTARY. Drugs used in VDLD (vincristine, daunorubicin, L-asparaginase, dexamethasone) chemotherapy and intrathecal therapy are likely risk factors for development of PRES in children treated for ALL., the onset in the present series occurring 7 to 30 days after VDLD therapy [ 1 ]. A previous report by Kim et al [ 2 ] analyzed predisposing factors of 19 pediatric ALL patients who developed PRES; they had all received induction chemotherapy.…”